Information  X 
Enter a valid email address

Oncimmune Hldngs PLC (ONC)


Monday 01 March, 2021

Oncimmune Hldngs PLC

Total Voting Rights

RNS Number : 5941Q
Oncimmune Holdings PLC
01 March 2021

1 March 2021



Oncimmune Holdings plc


("Oncimmune" or the "Company")


Total Voting Rights



In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.


Pursuant to the Company's existing block admission announced on 15 September 2020, and following the exercise of options over 47,647 ordinary shares in aggregate during February 2021 by current and former employees, as at 28 February 2021, the Company's issued share capital was 63,710,093 ordinary shares of £0.01 each with voting rights. The Company does not hold any shares in treasury.


The above figure of 63,710,093 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.



For further information:


Oncimmune Holdings plc

Ron Kirschner, Company Secretary

[email protected]


Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000


N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000


WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321


Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t